Dr. Rawizza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Brigham and Women's Hospital
75 Francis Street
Boston, MA 02115Phone+1 617-432-4686
Education & Training
- Massachusetts General Hospital/Brigham and Women's Hospital/Harvard Medical SchoolFellowship, Infectious Disease, 2005 - 2008
- Duke University HospitalResidency, Internal Medicine/Pediatrics, 2001 - 2005
- Vanderbilt University School of MedicineClass of 2001
Certifications & Licensure
- MA State Medical License 2007 - 2026
- NC State Medical License 2001 - 2005
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Start of enrollment: 2023 Jul 07
Roles: Principal Investigator, Contact
- Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention Start of enrollment: 2024 May 01
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 5 citationsPharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.Helena Rabie, Holly Rawizza, Peter Zuidewind, Jana Winckler, Heather J. Zar
The Journal of Antimicrobial Chemotherapy. 2019-08-01 - 3 citationsOut of Sight: Culture-Negative Endocarditis and Endophthalmitis.Caitlin M Dugdale, Sarah Brown, Carine Davila, Natalie Wolkow, Gregory A. Fishbein
The American Journal of Medicine. 2017-02-01 - 114 citationsImmunologic Criteria Are Poor Predictors of Virologic Outcome: Implications for HIV Treatment Monitoring in Resource-Limited SettingsHolly Rawizza, Beth Chaplin, Seema T. Meloni, Geoffrey Eisen, Tara Rao
Clinical Infectious Diseases. 2011-12-15
Press Mentions
- Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB PreventionFebruary 29th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: